Aim immunotech receives orphan drug designation for ampligen (rintatolimod) for the treatment of ebola virus disease

Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system
AIM Ratings Summary
AIM Quant Ranking